Filing Details

Accession Number:
0002001011-24-000052
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-15 19:34:53
Reporting Period:
2024-05-13
Accepted Time:
2024-05-15 19:34:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1649903 E Matthew Korenberg 555 Heritage Drive
Suite 200
Jupiter FL 33458
President & Chief Operating No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-05-13 3,440 $84.54 100,421 No 4 S Direct
Common Stock Disposition 2024-05-14 13,638 $85.08 86,783 No 4 S Direct
Common Stock Disposition 2024-05-14 520 $85.68 86,263 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.5000 to $84.8750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.5950 to $85.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.6250 to $85.7650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.